🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →
S&P 500: 763.96 -1.2% NASDAQ 100: 704.47 -2.9% Dow Jones: 534.08 -0.5%

Acorn Capital Advisors - Q1 2026 13F Filings

AC

Acorn Capital Advisors, LLC

CIK: 0002054410
Address: New York New York 420 Lexington Avenue Suite 2626
$351.84 M
Portfolio Value
22
Assets Held
Reporting Period: Q1 2026
Filing Status:
Active
Last Updated: 08/14/2026

Portfolio Summary (Q1 2026)

View Full Portfolio Analysis

Top Buys

Q1 2026
1. JBIO Jade Biosciences
+$11.05 M
2. CADL Candel Therapeutics
+$4.51 M
3. URGN Urogen Pharma
+$4.05 M
4. KPTI Karyopharm Therapeutics
+$1.6 M
5. LONA Leonabio
+$1.37 M

Top Sells

Q1 2026
1. QTTB Q32 Bio
−$1.15 M
2. ACRV Acrivon Therapeutics
−$976,622
3. JSPR Jasper Therapeutics
−$330,000.01
4. CRDF Cardiff Oncology
−$323,999.99
5. X4 Pharmaceuticals
−$162,350.62

Asset Allocation

Stocks/ETFs
+19.21%
$351.84 M 100.00%
Options
$0 0.00%
Debt
$0 0.00%
Other
$0 0.00%

Sector Allocation (Stocks)

Acorn Capital Advisors Q1 2026 Filing Summary

Acorn Capital Advisors, LLC filed its 13F report for Q1 2026 on May 15, 2026. The portfolio totaled 351.84 M reflecting a +19.21% change from the prior quarter, spanning 22 assets. The top 10 holdings comprised 88.9% of the portfolio, with Financials as the largest sector allocation. Quarterly activity included 2 new positions and 1 complete exits.

Report Type

Status

Data Summary

Items:

Total Value:

Actions

Issuer Name Class Value Shares Option Type

FAQs for Acorn Capital Advisors’s Q1 2026 Filing

Acorn Capital Advisors submitted their Form 13F-HR for the Q1 2026 period on 05/15/2026. This was the only submission for the quarter.

In the Q1 2026 filing, Acorn Capital Advisors reported a managed portfolio value of 351.84 M, consisting of 22 individual positions.

This page displays the raw filing documents. To see which stocks Acorn Capital Advisors bought or sold during Q1 2026, please visit Acorn Capital Advisors's Portfolio Analysis page.